PaxMedica reports first patient treated with PAX-101 for HAT
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 27 2024
0mins
Should l Buy ?
Milestone in Treatment: PaxMedica has achieved a significant milestone as a patient in Malawi, suffering from African Sleeping Sickness, has successfully received treatment with PAX-101 and is now recovering at home.
Importance of Suramin: The Rhodesiense strain of Human African Trypanosomiasis is nearly 100% fatal if untreated, making Suramin the standard care in Malawi and East Africa for early-stage infections to prevent death.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
